Skip to content
OpenCapital
Get started

Protagonist Therapeutics PTGX Q4 2025 Annual earnings

Reported February 25, 2026 · Before market open

Revenue$7.4MMiss by $1.3M
EPS-$0.69Miss by $0.16
Revenue estimate$8.7M
EPS estimate-$0.53

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$199.8M
EPS estimate$2.11

Financials

Q4 2025

Income statement

See full
Revenue$7.4M-95.6%
Operating income-$50.4M-140%
Net income-$44.4M-134%
EPS (diluted)-$0.70-135%

Balance sheet

See full
Cash & equivalents$128.4M+32.0%
Total debt$10.3M-5.0%
Total equity$614.7M-9.0%
Total assets$668.2M-10.3%

Cash flow

See full
CapEx$144.0K-53.5%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$5.46B+137%
Enterprise value$5.34B+141%
P/S118.7×+113×

Profitability

See full
Operating margin-343.6%-402pp
Net margin-282.8%-346pp

Returns & leverage

See full
Return on equity-20.2%-74.6pp
Debt / equity0×0.0×
Current ratio12.7×+0.2×

Segments

By segment

See full
Single Reportable$7.4M-95.6%

Versus estimates

Revenue

Q1 2026$56.4MBeat by $44.7M
Q4 2025$7.4MMiss by $1.3M
Q3 2025$4.7MMiss by $10.2MQ2 2025$5.5MMiss by $2.9MQ1 2025$28.3MBeat by $21.8MQ4 2024$170.6MBeat by $89.6M

Diluted EPS

Q1 2026$0.05Beat by $0.70
Q4 2025-$0.69Miss by $0.16
Q3 2025-$0.62Miss by $0.03Q2 2025-$0.55Miss by $0.02Q1 2025-$0.19Beat by $0.31Q4 2024$1.98Beat by $1.92

Ask the moment Protagonist Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Protagonist Therapeutics report Q4 2025 earnings?
Protagonist Therapeutics (PTGX) reported Q4 2025 earnings on February 25, 2026 before market open.
What were Protagonist Therapeutics's Q4 2025 revenue and EPS?
Protagonist Therapeutics reported revenue of $7.4M and eps of $-0.69 for Q4 2025.
Did Protagonist Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $8.7M by $1.3M. EPS missed the consensus estimate of $-0.53 by $0.16.
How did Protagonist Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 95.6% from $170.6M a year earlier.
Where can I find Protagonist Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-019658) and the 10-K periodic report (0001104659-26-019696) directly on SEC EDGAR. The filing index links above go to sec.gov.